Do high serum levels of anti-Saccharomyces cerevisiae antibodies result from a leakiness of the gut barrier in Crohn's disease?

European Journal of Gastroenterology and Hepatology

Volumn 15, Issue 12, 2003, Pages 1281-1285

  Harrer, Marieluise ^a   Reinisch, Walter ^a   Dejaco, Clemens ^a   Kratzer, Verena ^a   Gmeiner, Maria ^a   Miehsler, Wolfgang ^a   Norman, Gary L ^b   Gangl, Alfred ^a   Vogelsang, Harald ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b INOVA DIAGNOSTICS INC   (United States)

Author keywords

Anti Saccharomyces cerevisiae antibodies; ASCAs; Crohn's disease; Intestinal permeability

Indexed keywords

BACTERIUM ANTIBODY; IMMUNOGLOBULIN G; LACTULOSE; MANNITOL;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CHI SQUARE DISTRIBUTION; COLON CROHN DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FEMALE; HUMAN; HYPOTHESIS; IMMUNOGLOBULIN BLOOD LEVEL; INTESTINE MUCOSA PERMEABILITY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MEDICAL ASSESSMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SAMPLE SIZE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, FUNGAL; C-REACTIVE PROTEIN; CROHN DISEASE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTESTINAL ABSORPTION; MIDDLE AGED; PERMEABILITY; RETROSPECTIVE STUDIES; SACCHAROMYCES CEREVISIAE;

EID: 1842430309     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200312000-00005     Document Type: Article

References (19)

1. Wyatt J, Vogelsang H, Hubl W, Waldhoer T, Lochs H. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 1993; 341:1437-1439.
2. Bjarnason I, Marsh MN, Price A, Peters TJ. Intestinal permeability in patients with coeliac disease and dermatitis herpetiformis. Gut 1985; 26:1214-1219.
3. Hamilton I, Cobden I, Rothwell J, Axon AT. Intestinal permeability in coeliac disease. The response to gluten withdrawal and single-dose gluten challenge. Gut 1982; 23:202-210.
4. Strobel S, Brydon WG, Ferguson A. Cellobiose/mannitol sugar permeability test complements biopsy histopathology in clinical investigation of the jejunum. Gut 1984; 25:1241-1246.
5. Hollander D. Permeability in Crohn's disease: altered barrier functions in healthy relatives? Gastroenterology 1993; 104:1848-1873.
6. Peeters M, Geypens B, Claus D, Nevens H, Ghoos Y, Verbeke G, et al. Clustering of increased small intestinal permeability in families with Crohn's disease. Gastroenterology 1997; 113:802-807.
7. Main J, McKenzie H, Yeaman GR, Kerr MA, Robson D, Pennington CR, et al. Antibody to Saccharomyces cerevisiae (bakers' yeast) in Crohn's disease. BMJ 1988; 297:1105-1106.
8. Rutgeerts P, Vermeire S. Clinical value of the detection of antibodies in the serum for diagnosis and treatment of inflammatory bowel disease [Review]. Gastroenterology 1998; 115:1006-1009.
9. Sutton CL, Yang H, Li Z, Rotter JI, Targan SR, Braun J. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease. Gut 2000; 46:58-63.
10. Annese V, Andreoli A, Andriulli A, Dinca R, Gionchetti P, Latiano A, et al. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in Crohn's disease and ulcerative colitis: a GISC study. Am J Gastroenterol 2001; 96:2407-2412.
11. Ruemmele FM, Targan SR, Levy G, Dubinsky M, Braun J, Seidman EG. Diagnostic accuracy of serological assays in paediatric inflammatory bowel disease. Gastroenterology 1998; 115:822-829.
12. Vermeire S, Peeters M, Vlietinek R, Joossens S, Den Hond E, Bulteel V, et al. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. IBD 2001; 7:8-15.
13. Vermeire S, Joossens S, Peelers M, Monsuur F, Marien G, Bossuyt X, et al. Comparative study of ASCA (anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel disease. Gastroenterology 2001; 120:827-833.
14. Bjarnason I, Macpherson A, Hollander D. Intestinal permeability: an overview. Gastroenterology 1995; 108:1566-1581.
15. Vasiliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang H, Targan SR. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000; 47:487-496.
16. Darroch CJ, Barnes RMR, Dawson J. Circulating antibodies to Saccharomyces cerevisiae (bakers'/brewers' yeast) in gastrointestinal disease. J Clin Pathol 1999; 52:47-53.
17. Teahon K, Somasundaram S, Smith T, Menzies I, Bjarnason I. Assessing the site of increased intestinal permeability in coeliac and inflammatory bowel disease. Gut 1996; 38:864-869.
18. Miki K, Moore DJ, Butler RN, Southcott E, Couper RT, Davidson GP. The sugar permeability test reflects disease activity in children and adolescents with inflammatory bowel disease. J Pediat 1998; 133:750-754.
19. Halme L, Turunen U, Tuominen J, Forsstrom T, Turpeinen U. Comparison of iohexol and lactulose-mannitol tests as markers of disease activity in patients with inflammatory bowel disease. Scand J Clin Lab Invest 2000; 60:695-701.